Neurodegenerative disease and Neurodegeneration

Neurodegenerative disease is the group of condition or disease which mainly affect the neurons of the brain. The neurons are the building block of the brain and spinal cords or nervous system. Neurons are irreplaceable as they cannot replicate or reproduce after suffering damage which eventually death of the neuron.

Neurodegeneration is a loss in the structure and function of neurons.

Aging is the main cause of neurodegenerative disease. Neurodegenerative disease progress with age as the neurons become less functional. Oxidative stress, mitochondrial DNA mutation, and other factors lead a human body to age. Genetics, protein folding, DNA damage, mitochondrial dysfunction, programmed cell death, protein degradation pathways and other leads to the mechanism of neurodegenerative diseases. The cure of neurodegenerative disease is not yet discovered as causes of most of the cases are still a mystery.


  • Batten disease
  • Huntington's disease
  • Parkinson's disease
  • Amyotrophic lateral sclerosis (ALS)
  • Alzheimer's disease
  • Motor neuron disease

Market Analysis: Neurodegenerative diseases refer to a group of brain disorders that lead to progressive degeneration of the structure and function of neurons in the central nervous system (CNS) or peripheral nervous system (PNS). The global neurodegenerative disease treatment market grew at a CAGR of around 8% during 2015-2020. 
The Neurodegenerative Disease market was worth around USD 39.24 billion in 2020, and is predicted to reach USD 44.90 billion in 2026, with a CAGR of 2.30 percent.The global neurodegenerative disorder therapeutics market is predicted to increase at a compound annual growth rate (CAGR) of 7.9% from $14.08 billion in 2020 to $15.19 billion in 2021. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $20.15 billion in 2025 at a CAGR of 7%.

Muscular Dystrophy Conferences Neurology Conferences Europe Sleep Disorders Conferences Parkinson Disease Conferences Cerebrovascular Disease Conferences Neurology Conferences 2022 Europe Brain Cancer Conferences Neurology Conferences 2022 Neurophysiology Conferences Neurology Conferences 2022 Asia Child Psychology Conferences Euro Neurology Conferences Psychiatry Conferences Neuroscience Conferences 2021 Dubai Neurodegenerative Disorders Conferences